Provention Bio's TZIELD is the first and only therapy to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and pediatric patients aged 8 years and older with Stage 2 T1D. 

Individuals living in "extremely disadvantaged" ZIP codes are less likely to have access to accredited imaging facilities. 

The most recent updates contain “substantial new content and safety recommendations," the ACR reported recently. 

FloPatch is a wireless, wearable, FDA-approved doppler ultrasound system that attaches directly to a patient’s neck to continuously monitor carotid blood flow during intravenous fluid therapy.

According to the complaint, Rite Aid allegedly filled “at least” hundreds of thousands of unlawful prescriptions for controlled substances that lacked legitimate medical purpose, were not for a medically accepted indication or were not issued in the usual course of professional practice.

A new Alzheimer’s disease drug, Leqembi (lecanemab), will be covered by the Veterans Affairs for some patients, making the VA the first insurer to cover the drug.

Wary consumers can be convinced to allow AI into their healthcare habits by communications campaigns tuned to the ancient rhetorical categories of ethos, pathos and logos. 

Although advanced imaging exams have proven benefits in defining disease severity, new data indicate that more sophisticated studies might not impact outcomes as much as previously thought.